LAGUNA HILLS, Calif.—CODA Genomics and Chicago's Integrated Genomics announced an agreement that will see the two companies combine their protein production and yeast expression systems to address bottlenecks in the growing market for protein-based products, including biotherapeutics.
In particular, CODA scientists will re-engineer their Translation Engineering solution to work in Integrated Genomics' sequence informatics and microbial metabolic engineering systems to enhance protein production in Pichia.
"This combination of our proprietary Pichia sequence and metabolic reconstruction with CODA's unique expression optimization technology provides a tremendous opportunity for scientists optimizing protein expression in Pichia," said Dr. John Elling, president of Integrated Genomics.
According to a 2006 report by Kalorama Information, the market for protein-based therapeutics more than doubled to $51 billion between 2001 and 2005, and is expected to surpass $87 billion by 2010. "With little threat from generics due to the specialized manufacturing of cell lines and strong process controls, strong product innovation, and the premium pricing afforded to them due to their high-tech ingredient profiles and the diseases they target, we are witnessing a pharmacological wonder where everyone—including consumers—is a winner," said Steven Heffner, publisher for Kalorama.